Big performances last week from companies like OncoMed Pharma (OMED) and RetailMeNot (SALE) shows the continued strength of the IPO market. And as another sign of optimism, 11 deals are planned to go live this week.
Here’s a quick look at each:
Agios Pharmaceuticals is a pre-clinical biotech operator that uses cellular metabolism to treat cancer and other diseases. As a big validation, it formed a collaboration agreement with Celgene (CELG) back in April 2010. So far, AGIO has received $141.2 million in payments and $37.5 million in equity investments.
The founders of the company include some of the top scientists in the cellular metabolism field. They include Lew Cantley (director of the Cancer Center at Weill Cornell Medical College and New York Presbyterian Hospital), Tak Mak (professor of medical biophysics, University of Toronto) and Craig Thompson (president and CEO of Memorial Sloan-Kettering Cancer Center).
Cellular Dynamics International
Cellular Dynamics International has a propriety operating system that creates fully functioning human cells in industrial quantities. These are crucial for helping to research and test new drugs, as well as to allow for stem cell banking.
In 2012, revenues spiked 150% year-over-year to $6.6 million, but the company still lost $22.2 million last year.
Cellular Dynamics plans to issue 3.8 million shares on the Nasdaq under the ticker “ICEL” at a range of $12 to $14. The lead underwriter on the deal is JPMorgan.
Conatus Pharmaceuticals is a pre-clinical biotech company that is focused on treatments for liver disease. The lead product, emricasan, is in Phase 2b clinical trials and has been used by more than 500 subjects.
The core management team came from Idun Pharmaceuticals, which was sold to Pfizer (PFE) back in 2005 for $298 million. Two years later, they purchased the global rights to emricasan from the pharma giant.
CNAT plans to issue 5 million shares on the Nasdaq under the ticker “CNAT” at a range of $10 to $12. The lead underwriters include Stifel Nicolaus and Piper Jaffray (PJC).
Graña y Montero
Founded 80 years ago, Graña y Montero is Peru’s largest engineering and construction company. It has built some of the country’s landmark developments like the Lima International Airport and the Peru LNG gas liquefaction plant. During the past few years, GRAM has moved into the Chile by pulling off two major acquisitions. The company also has a strong presence in Columbia.
Last year, revenues climbed by 23% to $2 billion, and profits increased by 9% to $141.5 million.
Graña y Montero plans to issue 16.3 million shares on the New York Stock Exchange under the ticker “GRAM” at a range of $19.70 to $23.30. Lead underwriters include Credit Suisse (CS), JPMorgan, Morgan Stanley (MS) and BTG Pactual.
Heat Biologics is a development-stage biotech company that creates cellular therapeutic vaccines to combat cancer and infectious diseases. This involves using genetically modified, irradiated human cells, which are reprogrammed to pump out antigens.
Essentially, HTBX is leveraging a patient’s own immune system to fight cancer!
Heat Biologics plans to issue 2.3 million shares on the Nasdaq under the ticker “HBTX” at a range of $10 to $12. The lead underwriter is Aegis Capital.
Jones Energy is an independent oil & gas company that is engaged in production and acquisition in the Anadarko and Arkoma basins of Texas and Oklahoma. The CEO of the company, Jonny Jones, is a veteran of the energy business and founded his firm back in 1988.
From 2010 to 2012, revenues climbed from $98.5 million to $194.7 million, while adjusted EBITDA improved from $74 million to $177 million.
Liquid Holdings Group
Liquid Holdings Group operates a cloud-based platform to help traders with accounting, reporting and risk management. It is available for all the major asset classes like equities, options, futures, fixed income and foreign exchange.
As a note, the company is fairly small. For Q1, total revenues came to only $1.8 million, and the company suffered a net loss of $5.1 million and negative cash flows of $2.7 million.
Liquid Holdings plans to issue 5 million shares on the Nasdaq under the ticker “LIQD” at a range of $9 to $11. The lead under is Sandler O’Neill.
Marlin Midstream Partners
Marlin Midstream Partners is a provider of natural gas gathering, transportation and processing services. This is done with various natural processing plants in Texas’ Panola and Tyler counties.
However, the volatility in the market has put pressure on Marlin’s financials. Last year, revenues were $51 million, compared to $65.8 million in 2011. Operating income also fell from $51.4 million to $49.6 million.
Marlin plans to issue 6.3 million shares on the Nasdaq under the ticker “FISH” at a range of $19 to $21. Lead underwriters include Stifel Nicolaus, Baird and Oppenheimer & Co.
Onconova Therapeutics is a clinical-stage company that is focused on developing small-molecule drug candidates to treat cancer. This is based on a proprietary chemistry platform that uses an extensive library of targeted anti-cancer agents. The goal is to find effective treatments without causing harm to normal cells.
Onconova plans to issue 4.6 million shares on the Nasdaq under the ticker “ONTX” at a range of $12 to $14. Lead underwriters include Citi (C) and Leerink Swann.
Phillips 66 Partners
Phillips 66 Partners is the pipeline and logistics division of Phillips 66 (PSX). To maximize income potential, the business is in the form of a master limited partnership.
In 2012, PSXP posted $80.1 million in revenues, up from $76 million in the prior year. During this period, EBITDA climbed from $44.6 million to $48 million.
Phillips 66 Partners plans to issue 15 million shares on the NYSE under the ticker “PSXP” at a range of $19 to $21. Lead underwriters include JPMorgan and Morgan Stanley.
WCI Communities is a luxury homebuilder of single- and multifamily homes along the coast of Florida, and also has a real estate brokerage and a title service operation. WCI currently owns or controls about 8,300 sites.
The rebound in the real estate market has certainly boosted WCIC’s fortunes. Revenues surged from $144.3 million in 2011 to $241 million last year. During this period, adjusted EBITDA went from -$18.9 million to $29.3 million in the black.
WCI Communities plans to issue 8.4 million shares on the NYSE under the ticker “WCIC” at a range of $21 to $23. The lead underwriters include Citi, Credit Suisse and JPMorgan.
Tom Taulli runs the InvestorPlace blog IPO Playbook. He is also the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities.